Language:

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib

Lipworth, Adam D. ; Robert, Caroline ; Zhu, Andrew X.

Oncology, 2009-01, Vol.77 (5), p.257-271 [Peer Reviewed Journal]

Basel, Switzerland: Karger

Full text available

Citations Cited by

Actions
1. Add to e-Shelf
2. Remove from e-Shelf
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib
Author: Lipworth, Adam D. ; Robert, Caroline ; Zhu, Andrew X.
Subjects: Antineoplastic Agents - adverse effects ; Benzenesulfonates - adverse effects ; Biological and medical sciences ; Chemotherapy ; Dermatology ; Drug Eruptions - drug therapy ; Drug Eruptions - etiology ; Drug Eruptions - pathology ; Erythema - chemically induced ; Erythema - drug therapy ; Erythema - pathology ; Feet ; Foot Dermatoses - chemically induced ; Foot Dermatoses - drug therapy ; Foot Dermatoses - pathology ; Hand Dermatoses - chemically induced ; Hand Dermatoses - drug therapy ; Hand Dermatoses - pathology ; Hands ; Humans ; Indoles - adverse effects ; Medical sciences ; Niacinamide - analogs & derivatives ; Paresthesia - chemically induced ; Paresthesia - drug therapy ; Paresthesia - pathology ; Phenylurea Compounds ; Prognosis ; Pyridines - adverse effects ; Pyrroles - adverse effects ; Review ; Risk Factors ; Side effects ; Skin involvement in other diseases. Miscellaneous. General aspects ; Syndrome ; Tumors
Is Part Of: Oncology, 2009-01, Vol.77 (5), p.257-271
Description: Hand-foot syndrome (HFS), also called hand-foot skin reaction, palmar-plantar erythrodysesthesia, acral erythema, and Burgdorf reaction, is a dose-limiting cutaneous toxicity of many chemotherapeutic agents. Recently, the multiple tyrosine kinase inhibitor class of novel targeted therapies, including sorafenib and sunitinib, has emerged as an important cause of HFS, with 10–28% of patients treated with sunitinib and 10–62% of patients treated with sorafenib reporting HFS. This review examines the epidemiology, clinical features, histopathology, pathogenesis models, prognostic implications, and management of HFS, with particular attention to HFS induced by sorafenib and sunitinib. The high prevalence of HFS reported by patients treated with these medications underscores the need for greater understanding of the pathogenesis and management of this syndrome.
Publisher: Basel, Switzerland: Karger
Language: English

Links

Back to results list

Previous Result 7 Next Go to Next page

Implemented by: Social Network Logos:

Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palmar-Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib

Lipworth, Adam D. ; Robert, Caroline ; Zhu, Andrew X.

Basel, Switzerland: Karger

Searching Remote Databases, Please Wait